Lakewood-Amedex Biotherapeutics, Inc.

• Lakewood-Amedex Presents Nu-3 Broad-Spectrum Antimicrobial Activi
  The National Law Review · 21 Oct 2026
• Lakewood-Amedex presents Nu-3 antimicrobial data at IDWeek 2026
  StreetInsider · 21 Oct 2026
• LABT Price Today: Lakewood-Amedex Biotherapeutics Inc. Stock Price, Quote & Chart | MEXC
  MEXC · 15 Oct 2026
• Lakewood-Amedex Announces Positive Preclinical Bisphosphocin® Com
  The National Law Review · 08 Oct 2026
• Lakewood-Amedex Biotherapeutics (LABT) FDA Approvals, PDUFA Dates & Drug Alerts 2026
  MarketBeat · 07 Oct 2026
• Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences
  Kitsap Sun · 02 Oct 2026
• Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences
  Morningstar · 01 Oct 2026
• Lakewood-Amedex CEO to present new antimicrobia...
  Pluang · 01 Oct 2026
• Lakewood-Amedex's Nu-3 shows strong antibacterial activity against resistant diabetic foot ulcer infections
  Pluang · 28 Sep 2026
• $Lakewood-Amedex Biotherapeutics (LABT.US)$
  Moomoo · 28 Sep 2026
• Lakewood-Amedex reports positive test data for Nu-3 antimicrobial By Investing.com
  Investing.com Canada · 28 Sep 2026
• Beyond Antibiotics: Lakewood-Amedex Advances Diabetic Foot Ulcer Trial
  Benzinga · 24 Sep 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →